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Abstract
N-acetylcysteine (NAC) is a well-known antidote for acetaminophen toxicity and is easily
available over the counter. It has antioxidant and anti-inflammatory properties and an
established tolerance and safety profile. Owing to its neuroprotective effects, its clinical use
has recently expanded to include the treatment of different psychiatric and non-psychiatric
disorders. Although a number of randomized controlled trials have documented the clinical
evidence for NAC, there are no reviews that summarize the evidence. The present scoping
review summarizes the study designs, the patient characteristics, the evidence and the
limitations in randomized controlled trials designed to explore the efficacy of NAC for
psychiatric conditions in the pediatric population.
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Introduction And Background
N-acetylcysteine (NAC) has been a well-known antidote for acetaminophen toxicity for the last
30 years [1]. Easily available over the counter, it has antioxidant and anti-inflammatory
properties and an established tolerance and safety profile [2-4]. Because of its neuroprotective
effects, its clinical use has recently been expanded to include the treatment of different
psychiatric and non-psychiatric disorders [1]. The NAC is a synthetic N-acetyl derivative of the
endogenous amino acid L-cysteine, which is a precursor of the antioxidant enzyme glutathione.
The glutathione (γ-L-glutamyl-L-cysteinyl-glycine) or glutathione (GSH) acts as the body’s
defense mechanism against the oxidant stress in several metabolic and pathological reactions
[4]. It exerts its antioxidant effects by regulating oxidative metabolism and glutamate
transmission and plays a rate-limiting role in the synthesis of glutathione, a naturally
occurring antioxidant [4-5].
Limited evidence has implicated reactive oxygen species as a culprit in the neuronal
dysfunction responsible for several psychiatric and neurodevelopmental conditions [4]. In view
of the destructive neuronal effects of reactive oxygen species, the recent research has explored
the clinical efficacy of NAC in different neuropsychiatric conditions. The NAC has been found
to permeate the blood-brain barrier and has good bioavailability [4]. After intravenous
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administration, the mean elimination half-life of NAC is 5.6 hours in adults and 11 hours in
neonates [6]. It exerts its neuronal influence by converting L-cysteine to cysteine, facilitating
its uptake by glial cells and consequently allowing the glutamate release, which in turn
stimulates inhibitory glutamate receptors [4]. Due to these metabotropic glutamate receptors,
there is a reduction in the vesicular release of glutamate, resulting in the decrease in
glutamatergic neurotransmission [5]. This mechanism of action of NAC is particularly
important because of its effect on glutaminergic neurons in the nucleus accumbens, which is
involved in the modulation of the reward and reinforcement center implicated in the addictive
behaviors [2]. 
Several studies have associated the NAC with a reduction in the severity of the symptoms of
schizophrenia, bipolar disorders, Alzheimer’s, autism and substance abuse (cannabis and
cocaine) [6]. In this review, we briefly present recent progress in the use of NAC for different
psychiatric disorders in the pediatric population. We also aim to highlight the characteristics of
the patient populations, the outcome measures, drug regimens and adverse events reported in
the trials reviewed here. Table 1 summarizes the characteristics of the studies we included, the
doses of NAC, the results, and the limitations.
Study Condition
Sample
size
Dose of NAC
(mg/day)
Duration Results of study Limitations
Adjunct
medications
Hardan, et
al. 2012
ASD 33
1st week- 900 mg/ day
2nd week - 1800 mg/day
3rd week- 2700 mg three
times a day
12
weeks
Improvement in irritability
with NAC. Decreased
episodes of
repetitive/stereotype
behavior
Small sample
size  
Concomitant
use of
psychotropic
medications
and behavioral
interventions
Use of
medications, most
commonly 2nd
generation
antipsychotics
and SSRIs
Ghanizadeh
& Moghimi-
Sarani 2013
ASD 40 1200mg 8 weeks
Improvement in irritability
with NAC & Risperidone
Small Sample
size Short
duration Low
dose of NAC
Medications with
glutamatergic
effects was not
allowed Stable
doses of other
medications
Nikoo, et al.
2015
ASD 40
Dose of risperidone was
from 1 and 2.0 mg/d, and
the dose of NAC was 600
to 900 mg/d
10
weeks
The significant reduction in
irritability with NAC &
Risperidone.           Lack of
improvement in
lethargy/social withdrawal
subscale. No improvement in
stereotypic behaviors.
Reduction in hyperactivity
and non-compliance. No
improvement in inappropriate
speech  
Short duration
of study Small
sample size  
Taking
concomitant
medications with
glutamatergic
effects were not
allowed
Dose of NAC was 300-
No improvement in social
impairment.
No difference  in GSH/GSSG
High attrition
rates Small
Stimulants, alpha-
2 agonist,
antipsychotics,
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Wink, et al.
2016
ASD 31 600 mg/ daily target dose
of 60 mg/kg/day,
reaching to 4200mg/day
12
weeks
ratio, strand break, oxidative
damage of
deoxyribonucleic acid (DNA),
and blood homocysteine
between both groups
sample size.
Higher IQ in
majority of
participants
sleep aids,
antidepressants,
anti-epileptic
medications
Dean, et al.
2016
ASD 102 500 mg
6
months
No significant improvement
were found on the primary
outcomes of communication,
social interaction,  repetitive
behaviors and parent/clinical
global impression
Low dose of
NAC.       High
attrition rates 
 
Bloch, et al.
2013
Trichotillomania 39
600 mg at dinner for one
week, then 600 mg twice
a day for one week, then
600 mg in the morning
and at dinner for one
week, and then remained
on a dose of 1200 mg
twice a day for the
remainder of the 12-
week study
12
weeks
No significant changes in
hair-pulling severity were
reported over the follow-up
period
Strong
possibility of
Type I and II
error without
appropriate
statistical
correction
SSRIs,
antipsychotics,
psychostimulants,
and atomoxetine  
Ghanizadeh,
et al. 2013
Nail biting 42 800mg/day
2 
months
Lack of improvement in nail-
biting
Higher rates of
loss to follow-
up. Psychiatric
comorbidity
lower doses of
NAC shorter
duration of
exposure
Were allowed to
continue
medications.
Detail was not
mentioned
Bloch, et al.
2016
Tourette
syndrome
39 2400 mg
12
weeks
No significant difference
between NAC  and placebo
in reducing tics
Inadequate
assessment of
compliance.       
      Difference in
the severity of
anxiety at
baseline
between
placebo and
intervention
group  
Antidepressants,
stimulants,
antipsychotics
and alpha 2
agonists
Grey, et al.
2012
Cannabis use 116 2400 mg 8 weeks
Weekly negative urinary
cannabinoid tests shows
the beneficial effect of NAC.
Improvement in self-reported
days of cannabis use and
craving favored NAC, though
without reaching statistical
significance  
Short duration.  
Single site study
 
Not mentioned
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Roten, et al.
2013
Cannabis-
related
cravings
89 2400 mg 8 weeks
A significant improvement in
marijuana craving
questionnaire scores over the
course of the treatment,
there was no significant
differential change between
the NAC and placebo groups
MCQ was
validated in
adult non-
treatment
seekers but it
was used to
measure
craving in our
study in
adolescent
treatment
seekers
Not mentioned
Roten, et al.
2015
Neurocognitive
performance in
cannabis users
78 2400 mg 8 weeks
Significant improvement in
cognition like verbal memory,
composite memory and
psychomotor performance
with NAC
Less power to
detect
differences. The
absence of data
about cognitive
performance
prior to using
marijuana.
Absence of
non-marijuana
using controls
Not mentioned
McClure, et
al. 2014
 Smoking
cessation in
cannabis users
116 2400 mg 8 weeks
No change in cigarettes per
day for either NAC or placebo
groups
High attrition
rates   Smoking
cessation was
not primary
outcome  
Not mentioned
TABLE 1: Summary of the sample sizes, doses of N-acetylcysteine, results, and the
limitation of randomized controlled trials.
ASD: Autism spectrum disorder, NAC: N-acetylcysteine, MCQ: Marijuanna Craving Questionnaire, SSRI: selective serotonin
reuptake inhibitors.
Review
Autism spectrum disorder
Oxidative stress due to glutathione deficiency has been hypothesized to be a potential causal
factor in the pathogenesis of autism spectrum disorder (ASD) [5]. The glutathione has also been
linked to the frequent gastrointestinal and immunological dysfunctions in the people with
autistic disorder [5]. Therefore, the NAC can serve as a potential treatment option because of
its important rate-limiting role in glutathione metabolism. 
A search in PubMed with the search strategy (“N-acetylcysteine” or “NAC” and “autism”)
yielded five randomized controlled trials (RCTs). In a double-blind randomized controlled
trial by Hardan, et al. (2012), the efficacy of the oral NAC was assessed in physically healthy
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males and females aged three to 12 years with ASD, between March 2009 and September 2010
[5]. The primary outcome measures were the Aberrant Behavior Checklist (ABC) score to assess
irritability and the Dosage Record Treatment Emergent Symptom (DOTES) scale score to record
the severity of the side effects [5]. The participants were randomized to the NAC treatment
(n=14) or a placebo group (n=15) in a 12-week double-blind RCT. The initial dose of NAC was
900 mg per day for the first four weeks, which was increased to 900 mg twice daily for the next
four weeks, and 900 mg three times per day for the following four weeks. The clinical evaluation
was done at the baseline and at weeks four, eight, and 12. This study reported a significant
improvement in irritability in the NAC group, manifested as a lower ABC irritability subscale
score and a decrease in the number of repetitive/stereotyped behaviors (Cohen’s d=0.96) [5].
Although this RCT was statistically underpowered, the authors reported low bias related to
randomization, allocation concealment, attrition and blinding of the participants and
personnel toward the outcome assessment. There was no statistically significant difference
between the placebo and intervention groups in the frequency of the side effects.
Ghanizadeh & Moghimi-Sarani (2013) studied the efficacy of the NAC as an adjuvant in
children and adolescents with autism who were treated with risperidone to decrease irritability
in an eight-week double-blind RCT. The participants of both genders aged between 3.5 to 16
years were recruited from the outpatient psychiatry clinics if they had no concomitant
medication prior to the enrollment. The intervention group received a combination of
risperidone and NAC (1200 mg/day) in two divided doses, while the control group received a
placebo with risperidone. The initial dose of risperidone was 0.5 mg/day and was gradually
titrated to 2 mg/day for the participants weighing less than 30 kg and 3 mg daily for those
weighing > 30 kg. The change in the ABC irritability subscale score was the primary outcome
measure. This study suggested that the use of the NAC as an oral supplement and adjuvant to
the current treatment for irritability was superior to the combination of risperidone and
placebo (effect size = 1.4). Mild adverse effects were constipation, increased appetite, fatigue,
nervousness and daytime sleepiness [6]. There was low bias related to randomization,
allocation concealment and blinding of the patients, parents, and assessors, but this study too
was underpowered and had attrition bias.
The effectiveness of the NAC as an adjunct to risperidone was assessed in another randomized,
double-blind, controlled trial [7]. The irritability was assessed with the ABC irritability subscale
in 40 children (after attrition) who were randomized to receive risperidone plus NAC or
risperidone plus placebo. The secondary outcome measures included the social withdrawal,
stereotypic behaviors, hyperactivity and inappropriate speech. The patients in both groups
received risperidone at an initial dose of 0.5 mg with stepwise titration of 0.5 mg/week for the
first three weeks. The maximum dose of risperidone was 1 mg/day for children weighing less
than 20 kg and 2 mg/day for those weighing ≥ 20 kg. The intervention group received 600 to 900
mg/day of NAC in three divided doses of 200 mg/dose for children weighing < 20 kg and 300
mg/day for those weighing ≥ 20 kg. The N-acetylcysteine was effective in improving irritability
compared to the placebo in this study (Cohen’s d=1.06). In addition, the
hyperactivity/noncompliance improved significantly in the intervention group compared to the
placebo group. The side-effect profile was mild and transient, with no substantial differences
between the intervention and placebo groups [7]. This study had a low risk of bias related to
randomization, allocation concealment and blinding of the participants and the study
personnel. However, significant bias was likely because of low statistical power and attrition
bias.
Wink, et al. (2016) designed a double-blind, placebo-controlled RCT to assess the effectiveness
of the NAC in improving social communication in the patients with autism. The participants
were children between the ages of four to 12 years who weighed ≥ 15 kg, and who had a
confirmed diagnosis of the autism, Asperger’s disorder or pervasive developmental disorder not
otherwise specified. All were judged to be moderately ill based on the Clinical Global
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Impression severity (CGI-S) subscale. The participants were allowed to take their concomitant
medications except for glutaminergic pathway modulators [4]. The patients were prescribed a
formulation of the NAC containing 300–600 mg in divided doses, with a daily target dose of 60
mg/kg and a maximum dose of 4200 mg/day. The participants who weighed 15–30 kg were
started on 300 mg/day, and those who weighed more than 30 kg were started on 600 mg/day.
The initial dose was continued for the first three weeks and then gradually increased and
continued for the nine-week study period. The primary outcome measure was social
impairment according to the CGI improvement (CGI-I) subscale. This study found no
significant improvement in the social impairment in children with autism who were treated
with the NAC compared to the placebo, although a marginally significant improvement was
seen at week eight with a P value of 0.07 [4]. This study also investigated the impact of NAC on
oxidative stress markers in peripheral and venous blood samples collected at baseline and week
12. The glutathione (Cohen’s d=0.64) and glutathione disulfide (GSSG) (Cohen’s d=0.88)
improved more in the intervention group than the placebo group. However, there was no
difference between groups in GSH/GSSG ratio, strand breaks, DNA oxidative damage or blood
homocysteine concentration [4]. A low risk was reported in connection with randomization,
allocation concealment and or blinding of the patients, parents, and personnel, but the study
was biased due to attrition and beta error.
Another placebo-controlled RCT assessed the efficacy of the NAC for core symptoms of ASD as
the primary outcome measure. The outcomes were assessed with the Social Responsiveness
Scale, Children’s Communication Checklist (second edition), and the Repetitive Behavior Scale-
Revised. A total of 102 children was allocated to the NAC or placebo group, and a dose of 500
mg/day for six months were used in the NAC group. This trial failed to show a statistically
significant benefit of the NAC in the management of core symptoms of the ASD. The side-effect
profile was similar in both the intervention and placebo groups [8]. The study had low
statistical power and a high rate of attrition, but there was the low risk of bias in
randomization, allocation concealment, and blinding of the patients and research personnel.
Trichotillomania
Trichotillomania is an impulse control disorder characterized by the chronic hair-pulling,
distress and functional impairment [9]. The hair-pulling, which can occur in any area of the
body where hair grows, most commonly involves the scalp followed by the eyelashes and
eyebrows [10]. There is limited evidence for the effectiveness of the NAC treatment in pediatric
and adult populations, and the results published to date have been mixed [11-14]. However,
one study found that the NAC decreased the extracellular concentration of the glutamate in the
nucleus accumbens, reducing the symptoms of compulsive behaviors such as trichotillomania
[15].
A PubMed search with keywords (“N-acetyl cysteine” or “NAC” and “trichotillomania”) yielded
14 articles including one RCT that met our inclusion criteria. A double-blind, placebo-
controlled trial by Bloch and colleagues enrolled 39 children and young adults and found no
significant difference in the reduction of hair-pulling between the NAC and placebo groups
[13]. In view of the mixed results, larger RCTs are needed to assess the effectiveness of the NAC
for treating trichotillomania.
Pathological onychophagia
Onychophagia, a behavioral disorder in the children and young adults, is characterized by a
compulsion leading to habitual nail-biting. By the age of 18 years, the frequency of this
behavior decreases, but it may persist in some adults. It is an under-recognized problem with a
three-month prevalence of 22.3% in the males and females [16]. The pharmacological options
to treat nail-biting or onychophagia are limited [16]. Using the keywords (“N-acetylcysteine” or
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“NAC” and “onychophagia”), we were able to identify one suitable RCT out of six search entries
in the PubMed.
There is limited evidence for the efficacy of the NAC in onychophagia. A study by Ghanizadeh,
et al. (2013) explored the efficacy of the NAC in the treatment of nail-biting in a two-month
double-blind, placebo-controlled trial [16]. This study recruited 25 children and adolescents
aged six to 18 years, with a history of chronic nail-biting that caused emotional distress and
physical damage but without serious medical illness. Concomitant medications were allowed
during the trial, and participants were informed about the primary outcome and requested not
to cut their nails. In the NAC group, nine children received concurrent medication, including
citalopram, fluoxetine, nortriptyline, methylphenidate, risperidone, and atomoxetine. The N-
acetylcysteine was given at the dose of 800 mg/day with an initial dose of 200 mg/day. The
outcome measure was the length of all nails in millimeters, measured twice in each session. A
headache and aggressive behavior were the most common adverse effects in the NAC group.
This study suggested that nail length increased more gradually in the NAC treatment group
compared to the placebo group during the first month, but no significant difference was found
in a follow-up assessment after two months. The N-acetylcysteine was thus found to be
effective in improving impulsiveness in nail-biting for a short period [16]. The study had low
power and high risk associated with attrition, but was double-blinded and randomized, and had
low risk associated with allocation concealment. It also had a few limitations: a) high levels of
psychiatric comorbidity, (b) low doses of NAC administered, and (c) short duration of the
treatment. Due to its very small sample size, no cause-effect relationship related to the adverse
effects of medication could be inferred from this study.
Pediatric Tourette syndrome
Tourette syndrome is a chronic disorder that starts in childhood and is characterized by motor
and vocal tics of variable frequency, persisting for more than one year [9]. It is often associated
with behavioral disorders, particularly obsessive-compulsive disorder (OCD) and attention
deficit hyperactivity disorder (ADHD). The PubMed searches with the keywords (“N-
acetylcysteine” or “NAC” and “Tourette”) yielded one suitable RCT for inclusion out of eight
entries. 
Considering the potential evidence in the spectrum of OCD, Bloch, and colleagues (2016)
studied the effectiveness of the NAC for the management of the pediatric Tourette syndrome in
a double-blind, placebo-controlled trial [3]. In their study, 31 children and adolescents aged
eight to 17 years were randomly allocated to receive NAC or a placebo for 12 weeks [3]. A
significant proportion of the participants had a comorbid disorder such as OCD and ADHD and
were receiving concurrent treatments such as psychological therapy, antidepressants,
stimulants, antipsychotics and alpha-2 agonists. The primary outcome measures were the Yale
Global Tic Severity Scale (YGTSS) score and the Total tic score. There was no significant
difference between the NAC and placebo groups in the reduction of tic severity [3]. Like
previously reported studies, this study was underpowered; however, other methodological
characteristics were of adequate quality. A headache was the only adverse effect, reported by
one participant in the NAC group. Inadequate assessment of compliance and differences
between the placebo and intervention groups in the severity of anxiety at baseline were major
limitations in this study.
Cannabis use disorder
Substance use disorder is defined as the recurrent use of alcohol and/or drugs that can cause
functional impairment such as health problems, disability, and failure to meet major
responsibilities at work, school or home. According to the Diagnostic and Statistical Manual of
Mental Disorders (DSM)-5, a diagnosis of substance use disorder is based on evidence of
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impaired control, social impairment, risky use and pharmacological criteria [9].
A PubMed search with the keywords (“N-acetyl cysteine” and “cannabis”) yielded 13 articles,
including four that met our inclusion criteria. The efficacy of NAC as a pro-drug for cannabis
use disorder and nicotine use disorder was studied in one clinical trial [2]. In this large double-
blind randomized trial, Gray, et al. administered 2400 mg/day of NAC or placebo for eight weeks
with 116 participants between 15 and 21 years old who were addicted to marijuana [2]. Both
groups also received a contingency management intervention and cessation counseling.
Significantly more participants in the NAC treatment group had a negative urine cannabinoid
test [2]. The measures of self-reported days of cannabis use and craving favored NAC, although
the differences compared to the placebo group did not reach statistical significance [2]. The
significant improvements in cognitive performance were seen in the early stages of the
treatment-associated abstinence [2]. 
Roten, et al. studied the role of NAC in controlling cravings in the patients who were dependent
on cannabis [17]. The participants in this double-blind RCT had a history of cannabis
dependence and were between 15 and 21 years old. All participants were given oral NAC at 1200
mg twice per day or a placebo for eight weeks and also received cessation counseling for less
than 10 min with the management intervention [17]. The Marijuana Craving Questionnaire
(MCQ) was used to assess cravings. This study did not find a decrease in marijuana craving in
the NAC treatment group compared to the placebo group [17]. In part of this study published as
a separate article, the role of NAC in improving cognitive performance was analyzed [18]. All
participants completed a cognitive task performance test and the computer-administered
computerized neurocognitive (CNS) vital signs battery test at baseline on their first
appointment and in weeks four and eight during the trial were done. The authors found
significant improvements in cognitive tasks such as verbal memory and psychomotor speed
within weeks of marijuana cessation [18]. Further analyses of data from this trial found that the
NAC treatment was associated with increased rates of abstinence in the individuals seeking
treatment for cannabis use disorder, although positive correlations were also found with low
impulsivity, high medication adherence, and negative urine cannabinoid test findings at
baseline [18].
The co-occurrence of cannabis and tobacco use is highly prevalent and is a major public health
issue. The clinical role of the NAC to treat nicotine use disorder was investigated in the patients
with a history of cannabis use [19]. This study recruited 116 participants, 15 to 21 years old,
who used cannabis regularly (> three days/week) and showed interest in the cannabis cessation
treatment [19]. The participants were allocated to the NAC or placebo group, and the dose of
NAC was 1200 mg twice per day with a matched placebo. The treatment continued for eight
weeks, and follow-up appointments were held in 12 weeks. The clinical assessment was based
on urine samples and the number of cigarettes per day [19]. This study suggested a decrease in
urges/craving to smoke cigarettes and cannabis but did not find a reduction in the number of
cigarettes smoked per day in either group.
Conclusions
Because of its antioxidant and glutamate modulating properties, the NAC has become a focus of
interest in recent studies designed to investigate the treatment options for the core symptoms
of ASD and comorbid irritability. Although the evidence available to date for its therapeutic
activity is marred by low statistical power, the NAC may be a potential treatment option as an
adjunct to antipsychotics in efforts to improve symptoms of irritability. Recent RCTs has
yielded mixed results for different outcomes, but these studies were limited by their small
sample sizes, short duration, different formulations of NAC, and different dosage regimens.
The children with ASD constitute a heterogeneous group of the patients with a range of
2017 Naveed et al. Cureus 9(11): e1888. DOI 10.7759/cureus.1888 8 of 10
strengths and challenges that impact the efficacy of the treatment. A few RCTs have reported
improvements in repetitive or stereotyped behaviors, lethargy, and social withdrawal in
addition to improvements in irritability. However, these results have generally not been
replicated in other studies. Future research should be conducted with appropriate doses of NAC
and longer follow-up periods to better document its potential benefits for the core treatment of
ASD. The N-Acetylcysteine was ineffective for the treatment of trichotillomania, habitual nail-
biting and pediatric Tourette syndrome. On the other hand, it has been tested for cannabis use
disorder and smoking cessation with favorable results. However, the clinicians should carefully
consider the benefits, risk factors and alternatives when recommending NAC as a treatment
option. The findings of the RCTs reviewed here need to be validated by carefully planned
studies with adequate sample sizes.
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